Oligorecurrent

The oligorecurrent phase is a relapsed phase of oligometastatic cancer [1]. «The conditions of oligorecurrence has a primary site of cancer controlled, meaning that all gross recurrent or metastatic sites could be treated using local therapy [2].»

«Schema 1 shows one distant metastasis/recurrence with a primary lesion. Schema 2 shows two distant metastases/recurrences with a primary lesion.»

Source: [2].

«Schema 1 shows one distant metastasis/recurrence with a controlled primary lesion. Schema 2 shows two distant metastases/recurrences with a controlled primary lesion. The biggest difference between oligometastases and oligo-recurrences lies in the uncontrolled or controlled primary lesion. Oligo-recurrence requires a controlled primary lesion.»

Source: [2].

According to the ESTRO-EORTC consensus [3]:

An oligorecurrent prostate cancer is «a metachronous hormone-sensitive metastatic prostate cancer with a limited number of metastases, all of which are amenable to intervention» [4].

Bibliographic references:

[1] Alongi F, Mazzola R, Figlia V, Guckenberger M. Stereotactic body radiotherapy for lung oligometastases: Literature review according to PICO criteria. Tumori. 2018 Jun;104(3):148-156. Available at: https://doi.org/10.1177/0300891618766820.

[2] Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010 Feb;40(2):107-11. Available at: https://doi.org/10.1093/jjco/hyp167.

[3] Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020 Jan;21(1):e18-e28. Available at: https://doi.org/10.1016/s1470-2045(19)30718-1.

[4] Kucharczyk MJ, So J, Gravis G, et al. A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. Radiother Oncol. 2020 Nov;152:80-88. Available at: https://doi.org/10.1016/j.radonc.2020.08.011.